NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance
about
Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925.A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells.Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function.Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.Cell-based high-throughput screens for the discovery of chemotherapeutic agents.Antiinfectives targeting enzymes and the proton motive force.PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cellsReversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells.Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats.Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expressionPossibilities to increase the effectiveness of doxorubicin in cancer cells killing.Investigational ABC transporter inhibitors.Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.Gambogic acid as a non-competitive inhibitor of ATP-binding cassette transporter B1 reverses the multidrug resistance of human epithelial cancers by promoting ATP-binding cassette transporter B1 protein degradation.Molecular insight into conformational transmission of human P-glycoprotein.Novel strategies to prevent the development of multidrug resistance (MDR) in cancer.
P2860
Q33750171-F600E734-0770-4B86-A1EF-EEECBF1B3B21Q34977187-D4E4455B-5315-41E8-967A-7FE3BD9D82E8Q35587385-25DA8713-5AD5-4D15-B807-1ED6DE9D431CQ35851832-9CBC50A9-2120-4D89-BB2E-DB853398BF33Q35930414-AB1C9E2A-78C4-4767-8DEE-4D71C31D7D06Q36071888-BA2611F3-9121-4265-BE06-EA148E195749Q36419761-14F58138-ECD5-4747-97EE-B6C7338B4990Q36738640-E3AA5C2B-AC55-4C49-ADF3-B06B2998AA01Q36843815-BB210B48-F97E-416A-AEA9-4EDEF9AE4F54Q36881996-AA6392D0-174A-451E-81C4-34D86DE04F46Q37696336-EB8B5837-A878-40E3-97BC-D326BFFC93F5Q37707677-027046D4-25E8-4C8B-96FA-90BA2C97C854Q37937579-48E498F8-3AC1-4441-90F7-C5043A24F2DEQ38001734-7205A870-C75C-45DC-A210-1AEA89480FDAQ38819410-06AB4FF3-738F-46D6-92A0-2E169AF78F15Q39320594-96B1F471-9FC9-4D2F-A7AB-1E1775DA6B5CQ44488182-987A39AE-2463-4889-8E5D-7A0083020CB4Q47129596-8A9DA483-01E2-4196-8C88-34949BADB38E
P2860
NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
NSC23925, identified in a high ...... reverses multidrug resistance
@ast
NSC23925, identified in a high ...... reverses multidrug resistance
@en
NSC23925, identified in a high ...... reverses multidrug resistance
@nl
type
label
NSC23925, identified in a high ...... reverses multidrug resistance
@ast
NSC23925, identified in a high ...... reverses multidrug resistance
@en
NSC23925, identified in a high ...... reverses multidrug resistance
@nl
prefLabel
NSC23925, identified in a high ...... reverses multidrug resistance
@ast
NSC23925, identified in a high ...... reverses multidrug resistance
@en
NSC23925, identified in a high ...... reverses multidrug resistance
@nl
P2860
P3181
P1433
P1476
NSC23925, identified in a high ...... reverses multidrug resistance
@en
P2093
Francis J Hornicek
P2860
P3181
P356
10.1371/JOURNAL.PONE.0007415
P407
P577
2009-10-12T00:00:00Z